TNSN07018A1 - New 4-benzylidene-piperidin derivatives - Google Patents
New 4-benzylidene-piperidin derivativesInfo
- Publication number
- TNSN07018A1 TNSN07018A1 TNP2007000018A TNSN07018A TNSN07018A1 TN SN07018 A1 TNSN07018 A1 TN SN07018A1 TN P2007000018 A TNP2007000018 A TN P2007000018A TN SN07018 A TNSN07018 A TN SN07018A TN SN07018 A1 TNSN07018 A1 TN SN07018A1
- Authority
- TN
- Tunisia
- Prior art keywords
- halogen atom
- benzylidene
- oxo
- optionally substituted
- formula
- Prior art date
Links
- QMQNIKYRPSFQKB-UHFFFAOYSA-N 4-benzylidenepiperidine Chemical class C1CNCCC1=CC1=CC=CC=C1 QMQNIKYRPSFQKB-UHFFFAOYSA-N 0.000 title abstract 6
- 125000005843 halogen group Chemical group 0.000 abstract 12
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 3
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 abstract 3
- 102000014649 NMDA glutamate receptor activity proteins Human genes 0.000 abstract 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 abstract 3
- 239000005557 antagonist Substances 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- -1 cyano, nitro, amino Chemical group 0.000 abstract 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 abstract 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- DNUJVGBNIXGTHC-UHFFFAOYSA-N 3,6-dihydro-2h-oxazine Chemical compound C1NOCC=C1 DNUJVGBNIXGTHC-UHFFFAOYSA-N 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 abstract 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 abstract 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 230000003287 optical effect Effects 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- UMURLIQHQSKULR-UHFFFAOYSA-N 1,3-oxazolidine-2-thione Chemical compound S=C1NCCO1 UMURLIQHQSKULR-UHFFFAOYSA-N 0.000 abstract 1
- WGJCBBASTRWVJL-UHFFFAOYSA-N 1,3-thiazolidine-2-thione Chemical compound SC1=NCCS1 WGJCBBASTRWVJL-UHFFFAOYSA-N 0.000 abstract 1
- 102100022630 Glutamate receptor ionotropic, NMDA 2B Human genes 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 abstract 1
- WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 abstract 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 abstract 1
- 108010038912 Retinoid X Receptors Proteins 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000004423 acyloxy group Chemical group 0.000 abstract 1
- 125000002905 alkanoylamido group Chemical group 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000004849 alkoxymethyl group Chemical group 0.000 abstract 1
- 125000003282 alkyl amino group Chemical group 0.000 abstract 1
- 125000005422 alkyl sulfonamido group Chemical group 0.000 abstract 1
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 abstract 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 1
- 125000001691 aryl alkyl amino group Chemical group 0.000 abstract 1
- 125000001769 aryl amino group Chemical group 0.000 abstract 1
- 125000005421 aryl sulfonamido group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 abstract 1
- NBGMRMDAEWWFIR-UHFFFAOYSA-N imidazole-2-thione Chemical compound S=C1N=CC=N1 NBGMRMDAEWWFIR-UHFFFAOYSA-N 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 abstract 1
- IMWUREPEYPRYOR-UHFFFAOYSA-N pyrrolidine-2-thione Chemical compound S=C1CCCN1 IMWUREPEYPRYOR-UHFFFAOYSA-N 0.000 abstract 1
- 125000003831 tetrazolyl group Chemical group 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU0401522A HUP0401522A2 (en) | 2004-07-29 | 2004-07-29 | New 4-benzylidene-piperidine derivatives, pharmaceutical compositions containing the same and process for their preparation |
| PCT/HU2005/000077 WO2006010964A1 (en) | 2004-07-29 | 2005-07-21 | New 4-benzylidene-piperidin derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TNSN07018A1 true TNSN07018A1 (en) | 2008-06-02 |
Family
ID=89985407
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNP2007000018A TNSN07018A1 (en) | 2004-07-29 | 2007-01-17 | New 4-benzylidene-piperidin derivatives |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US8008326B2 (enExample) |
| EP (1) | EP1773810B1 (enExample) |
| JP (1) | JP4814880B2 (enExample) |
| KR (1) | KR20070058428A (enExample) |
| CN (1) | CN1989128A (enExample) |
| AP (1) | AP2074A (enExample) |
| AT (1) | ATE387440T1 (enExample) |
| AU (1) | AU2005266159B2 (enExample) |
| BR (1) | BRPI0513902A (enExample) |
| CA (1) | CA2574148A1 (enExample) |
| CY (1) | CY1107368T1 (enExample) |
| DE (1) | DE602005005064T2 (enExample) |
| DK (1) | DK1773810T3 (enExample) |
| EA (1) | EA011241B1 (enExample) |
| ES (1) | ES2302214T3 (enExample) |
| GE (1) | GEP20084492B (enExample) |
| HR (1) | HRP20080127T3 (enExample) |
| HU (1) | HUP0401522A2 (enExample) |
| IL (1) | IL179484A0 (enExample) |
| MA (1) | MA28816B1 (enExample) |
| MX (1) | MX2007001055A (enExample) |
| NO (1) | NO20071108L (enExample) |
| NZ (1) | NZ552137A (enExample) |
| PL (1) | PL1773810T3 (enExample) |
| PT (1) | PT1773810E (enExample) |
| RS (1) | RS50573B (enExample) |
| SI (1) | SI1773810T1 (enExample) |
| TN (1) | TNSN07018A1 (enExample) |
| UA (1) | UA87862C2 (enExample) |
| WO (1) | WO2006010964A1 (enExample) |
| ZA (1) | ZA200700320B (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7935706B2 (en) | 2006-02-23 | 2011-05-03 | Shionogi & Co., Ltd. | Nitrogen-containing heterocycle derivatives substituted with cyclic group |
| CN101426381A (zh) * | 2006-04-21 | 2009-05-06 | 西诺米克斯公司 | 含有高效鲜味调料的可食用组合物及其制备方法 |
| EP2024355B1 (en) * | 2006-06-08 | 2010-07-14 | Bristol-Myers Squibb Company | Alkene piperidine derivatives as antiviral agents |
| JP2011527689A (ja) * | 2008-07-08 | 2011-11-04 | リヒター ゲデオン エヌワイアールティー． | ２−［４−（４−フルオロ−ベンジル）−ピペリジン−１−イル］−２−オキソ−ｎ−（２−オキソ−２，３−ジヒドロ−ベンゾオキサゾール−６−イル）−アセトアミドの結晶形態 |
| CN102762554A (zh) | 2010-02-16 | 2012-10-31 | 辉瑞大药厂 | 5-ht4受体的部分激动剂(r)-4-((4-((4-(四氢呋喃-3-基氧基)苯并[d]异*唑-3-基氧基)甲基)哌啶-1-基)甲基)四氢-2h-吡喃-4-醇 |
| CN103080086B (zh) | 2010-09-07 | 2014-11-05 | 大鹏药品工业株式会社 | 抑制前列腺素d合成酶的哌啶化合物 |
| US20120322824A1 (en) * | 2011-01-04 | 2012-12-20 | Surratt Christopher K | Cocaine Antagonist/Antidepressant Pharmaceutical Preparations |
| CA2869216A1 (en) | 2012-04-20 | 2013-10-24 | Ucb Pharma S.A. | Methods for treating parkinson's disease |
| JP6563017B2 (ja) | 2014-08-28 | 2019-08-21 | エースニューロン・ソシエテ・アノニム | グリコシダーゼ阻害剤 |
| US10913733B2 (en) | 2015-12-18 | 2021-02-09 | Alectos Therapeutics Inc. | Substituted piperidines thiazolyl acetamides as glycosidase inhibitors and uses thereof |
| CA3012560A1 (en) | 2016-02-25 | 2017-08-31 | Asceneuron S.A. | Glycosidase inhibitors |
| CA3012624A1 (en) | 2016-02-25 | 2017-08-31 | Asceneuron S.A. | Glycosidase inhibitors |
| US11261183B2 (en) | 2016-02-25 | 2022-03-01 | Asceneuron Sa | Sulfoximine glycosidase inhibitors |
| EP3419976B1 (en) | 2016-02-25 | 2021-04-07 | Asceneuron SA | Acid addition salts of piperazine derivatives |
| US9486444B1 (en) | 2016-03-21 | 2016-11-08 | King Saud University | Anti-cancer compound |
| WO2019037860A1 (en) | 2017-08-24 | 2019-02-28 | Asceneuron S.A. | LINEAR INHIBITORS OF GLYCOSIDASE |
| WO2020039028A1 (en) | 2018-08-22 | 2020-02-27 | Asceneuron S. A. | Tetrahydro-benzoazepine glycosidase inhibitors |
| US11731972B2 (en) | 2018-08-22 | 2023-08-22 | Asceneuron Sa | Spiro compounds as glycosidase inhibitors |
| KR102839500B1 (ko) | 2018-08-22 | 2025-07-28 | 아셰뉴론 에스아 | 글리코시다제 억제제로서 유용한 피페라진 유도체의 숙시네이트 및 푸마레이트 산 부가염 |
| US12016852B2 (en) | 2018-08-22 | 2024-06-25 | Asceneuron Sa | Pyrrolidine glycosidase inhibitors |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA9610738B (en) * | 1995-12-22 | 1997-06-24 | Warner Lambert Co | Subtype selective nmda receptor ligands and the use thereof |
| TW498067B (en) * | 1996-07-19 | 2002-08-11 | Hoffmann La Roche | 4-hydroxy-piperidine derivatives |
| CA2220649C (en) | 1996-12-03 | 2007-02-13 | F. Hoffmann-La Roche Ag | 4-hydroxy-piperidine derivatives |
| CZ2004233A3 (cs) * | 2001-07-24 | 2004-12-15 | Richter Gedeon Vegyészeti Gyár Rt. | Nové amidové sloučeniny karboxylové kyseliny |
-
2004
- 2004-07-29 HU HU0401522A patent/HUP0401522A2/hu unknown
-
2005
- 2005-07-21 DE DE602005005064T patent/DE602005005064T2/de not_active Expired - Lifetime
- 2005-07-21 AP AP2006003839A patent/AP2074A/en active
- 2005-07-21 AT AT05763197T patent/ATE387440T1/de active
- 2005-07-21 UA UAA200702171A patent/UA87862C2/ru unknown
- 2005-07-21 MX MX2007001055A patent/MX2007001055A/es active IP Right Grant
- 2005-07-21 PL PL05763197T patent/PL1773810T3/pl unknown
- 2005-07-21 NZ NZ552137A patent/NZ552137A/xx not_active IP Right Cessation
- 2005-07-21 ES ES05763197T patent/ES2302214T3/es not_active Expired - Lifetime
- 2005-07-21 EA EA200700367A patent/EA011241B1/ru not_active IP Right Cessation
- 2005-07-21 US US11/658,789 patent/US8008326B2/en not_active Expired - Fee Related
- 2005-07-21 EP EP05763197A patent/EP1773810B1/en not_active Expired - Lifetime
- 2005-07-21 WO PCT/HU2005/000077 patent/WO2006010964A1/en not_active Ceased
- 2005-07-21 BR BRPI0513902-3A patent/BRPI0513902A/pt not_active IP Right Cessation
- 2005-07-21 PT PT05763197T patent/PT1773810E/pt unknown
- 2005-07-21 KR KR1020077000262A patent/KR20070058428A/ko not_active Ceased
- 2005-07-21 GE GEAP20059892A patent/GEP20084492B/en unknown
- 2005-07-21 CA CA002574148A patent/CA2574148A1/en not_active Abandoned
- 2005-07-21 DK DK05763197T patent/DK1773810T3/da active
- 2005-07-21 JP JP2007523160A patent/JP4814880B2/ja not_active Expired - Fee Related
- 2005-07-21 RS RSP-2008/0123A patent/RS50573B/sr unknown
- 2005-07-21 SI SI200530213T patent/SI1773810T1/sl unknown
- 2005-07-21 HR HR20080127T patent/HRP20080127T3/xx unknown
- 2005-07-21 AU AU2005266159A patent/AU2005266159B2/en not_active Ceased
- 2005-07-21 CN CNA2005800243746A patent/CN1989128A/zh active Pending
-
2006
- 2006-11-22 IL IL179484A patent/IL179484A0/en unknown
-
2007
- 2007-01-11 ZA ZA200700320A patent/ZA200700320B/en unknown
- 2007-01-17 TN TNP2007000018A patent/TNSN07018A1/en unknown
- 2007-02-22 MA MA29703A patent/MA28816B1/fr unknown
- 2007-02-27 NO NO20071108A patent/NO20071108L/no not_active Application Discontinuation
-
2008
- 2008-03-27 CY CY20081100349T patent/CY1107368T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TNSN07018A1 (en) | New 4-benzylidene-piperidin derivatives | |
| TNSN07016A1 (en) | Indole-2-carboxamidine derivatives as nmda receptor antagonists | |
| ES2617873T3 (es) | Composiciones y métodos para tratar trastornos de alcoholismo, dolor y otras enfermedades | |
| JP5927174B2 (ja) | 二環式部分を持つｔｒｐｖ１バニロイド受容体拮抗薬 | |
| HRP20040178B1 (hr) | Derivati piperidina kao antagonisti nmda receptora | |
| KR20220148847A (ko) | 다브라페닙, erk 억제제, 및 shp2 억제제를 포함하는 삼중 약학적 조합물 | |
| KR20230170039A (ko) | Egfr 돌연변이를 지니는 암을 치료하기 위한 아미노-치환된 헤테로사이클 | |
| KR20210137422A (ko) | 티로신 키나아제 억제제로서의 퀴나졸린 유도체, 조성물, 이들의 제조 방법 및 이들의 용도 | |
| TNSN07014A1 (en) | New heterocyclic carboxylic acid amide derivatives | |
| RU2014105624A (ru) | Соединения индазола, способ их применения и фармацевтическая композиция | |
| JP2007502807A5 (enExample) | ||
| RU2008142600A (ru) | Органическое соединение | |
| RU2006133898A (ru) | Производные бензимидазола и его применение | |
| ATE294796T1 (de) | Chinazolin derivate | |
| AR074876A1 (es) | Derivados de indol-pirimidina para tratar cancer | |
| JP2015503507A5 (enExample) | ||
| DE60320012D1 (de) | Aminoheterocyclen als vr-1 antagonisten zur behandlung von schmerzen | |
| RU2009103300A (ru) | Производные 2-бензоилимидазопиридинов, их получение и их применение в терапии | |
| MX2009006319A (es) | Derivados de 5-[4-(azetidin-3-iloxi)-fenil] -2-fenil-5h tiazolo [5,4-c] piridin-4-ona y su uso como antagonistas del receptor de mch. | |
| RU2011112684A (ru) | АГЕНТ, СПОСОБСТВУЮЩИЙ РОСТУ ВОЛОС, СОДЕРЖАЩИЙ В КАЧЕСТВЕ АКТИВНОГО ИНГРЕДИЕНТА ПРОИЗВОДНОЕ 15,15-ДИФТОРПРОСТАГЛАНДИНА F2α | |
| JP6526789B2 (ja) | 組み合わせ療法 | |
| TNSN07017A1 (en) | New benzoyl urea derivatives | |
| ATE338042T1 (de) | Hetero-bicyclische crf antagonisten | |
| NO20063597L (no) | Acetylinske piperazinforbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister | |
| EA019037B1 (ru) | 5-[5-[2-[3,5-бис(трифторметил)фенил-2-метилпропаноилметиламино]-4-(4-фтор-2-метилфенил)]-2-пиридинил]-2-алкилпролинамиды в качестве антагонистов рецептора nk1 |